236 related articles for article (PubMed ID: 29797763)
21. Quantitative Evaluation of Combretastatin A4 Phosphate Early Efficacy in a Tumor Model with Dynamic Contrast-Enhanced Ultrasound.
Zhang P; Chen Y; Liu J; Yang Y; Lv Q; Wang J; Zhang L; Xie M
Ultrasound Med Biol; 2018 Apr; 44(4):840-852. PubMed ID: 29395676
[TBL] [Abstract][Full Text] [Related]
22. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
Hill SA; Chaplin DJ; Lewis G; Tozer GM
Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236
[TBL] [Abstract][Full Text] [Related]
23. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.
Williams LJ; Mukherjee D; Fisher M; Reyes-Aldasoro CC; Akerman S; Kanthou C; Tozer GM
Br J Pharmacol; 2014 Nov; 171(21):4902-13. PubMed ID: 24930520
[TBL] [Abstract][Full Text] [Related]
24. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
25. The development of combretastatin A4 phosphate as a vascular targeting agent.
Chaplin DJ; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
[TBL] [Abstract][Full Text] [Related]
26. Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Salmon BA; Siemann DW
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):211-7. PubMed ID: 17448875
[TBL] [Abstract][Full Text] [Related]
27. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
Anderson HL; Yap JT; Miller MP; Robbins A; Jones T; Price PM
J Clin Oncol; 2003 Aug; 21(15):2823-30. PubMed ID: 12807935
[TBL] [Abstract][Full Text] [Related]
28. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
29. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.
Nabha SM; Mohammad RM; Wall NR; Dutcher JA; Salkini BM; Pettit GR; Al-Katib AM
Anticancer Drugs; 2001 Jan; 12(1):57-63. PubMed ID: 11272287
[TBL] [Abstract][Full Text] [Related]
31. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
Shen Y; Wu L; Qiu L
J Pharm Sci; 2017 Oct; 106(10):3076-3083. PubMed ID: 28619603
[TBL] [Abstract][Full Text] [Related]
32. Correlation of quantified contrast-enhanced power Doppler ultrasonography with immunofluorescent analysis of microvessel density in spontaneous canine tumours.
Ohlerth S; Wergin M; Bley CR; Del Chicca F; Laluhová D; Hauser B; Roos M; Kaser-Hotz B
Vet J; 2010 Jan; 183(1):58-62. PubMed ID: 18922713
[TBL] [Abstract][Full Text] [Related]
33. Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions.
Feng D; Menger MD; Laschke MW
Fertil Steril; 2013 Nov; 100(5):1459-67. PubMed ID: 23993929
[TBL] [Abstract][Full Text] [Related]
34. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
35. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.
Xu XP; Wu XD; Liang GL; Huang WS; Wang L; Jing HY; Zhong SL
Pharmazie; 2012 Jun; 67(6):529-33. PubMed ID: 22822542
[TBL] [Abstract][Full Text] [Related]
37. Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Busk M; Bohn AB; Skals M; Wang T; Horsman MR
Vascul Pharmacol; 2011; 54(1-2):13-7. PubMed ID: 21040805
[TBL] [Abstract][Full Text] [Related]
38. Transcatheter Arterial Embolization Combined with Anti-vascular Agent Combretastatin A4 Phosphate Inhibits Growth and Vascularization of Liver Tumor in an Animal Model.
Zhao H; Wu ZZ; Ren Q; Wu JJ; Wang Y; Feng JW; Rao M; Deng Q; Hu HY
Curr Med Sci; 2022 Dec; 42(6):1240-1247. PubMed ID: 36462132
[TBL] [Abstract][Full Text] [Related]
39. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
[TBL] [Abstract][Full Text] [Related]
40. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
